|
Patent landscape, scope, and claims summary: |
United States Patent 10,179,770: Claim Scope, Critical Strengths and Weaknesses, and US Landscape
What does US 10,179,770 actually claim?
US 10,179,770 claims a family of substituted quinoline compounds defined by a Markush-style core of “formula (I)” (claim 1), with downstream dependent claims locking in subsets (claim 2), enumerated exemplars (claims 3-4), additional sub-formulae (claims 5-8), and a broad downstream set of composition and method claims (claims 9-29). The core structure repeatedly includes:
- A quinoline scaffold
- A 2-substituted aryl group (R¹-like selection appears to govern the “aryl/heteroaryl/heteroaromatic 5-9 membered ring” substitution patterns)
- A 4-position substituent that is typically a piperidine or related amine-containing moiety (R⁴/R⁵/L² definitions and the enumerated examples show tertiary amines and bicyclic amines)
- Optional 7-position substitution (many exemplars are 7-chloro or 7-substituted)
- Salts/prodrugs/solvates are included across the claim chain
Core claim architecture
- Claim 1: Markush definition of a compound of formula (I), plus salts/solvates/prodrugs.
- Claim 2: Another Markush formula (I') limited by L¹/L²/R¹/R²/R⁴/R⁵/n as defined in claim 1.
- Claims 3-4: Enumerated chemical examples (freebases and salts).
- Claims 5-8: Specific sub-formulas (Ia)-(Id) each tied to one of the enumerated items (XIX-2, XLV-1, XII-3, XXIV-2).
- Claims 9-24: Broad pharmaceutical composition claims including nanoparticle formulations, PLGA/PLA-PGA, PEG association, size range 80-600 nm, slow/sustained-release, and inclusion in combination with “anti-neoplastic agents.”
- Claims 25-29: Method of treatment and/or prevention across “proliferative and/or neoplastic disease,” then broad cancer categories and specific disease exemplars, plus a CSC inhibition framing.
How broad is the chemical scope and where does it concentrate risk?
Markush breadth in claim 1
Claim 1 is highly permissive in substituent selection:
- R¹: optionally substituted aryl or heteroaryl/heteroaromatic 5-9 member ring with 1-3 O/N/S atoms
- R²: wide halogen/alkyl/alkoxy/hydroxy/nitro/amino-acyl/oxy-carbonyl-sulfonyl-lipid like classes
- L¹ / L²: multiple “bond or substituted alkyl(-R³), N(-R³), (CO)-O, (CO)-NR⁷, O” options
- R³: H, aryl, heteroaryl, heterocycloalkyl, C1-C8 alkyl, alkenyl/alkynyl, cycloalkyl/cycloalkenyl
- R⁷/R⁸: H or C1-C6 alkyl or phenyl/benzyl optionally substituted with a list of halogens/alkyl/alkoxy/hydroxy/cyano/nitro/NR⁷R⁸
- R⁴/R⁵: H, C1-C6 alkyl or phenyl/benzyl and extended linkages where R⁴ and R⁵ can link to form a heterocycle
Where scope is strongest
The claim is strongest where chemistry is concentrated but still flexible:
- The functional theme is consistent across the enumerated examples: quinoline + substituted phenyl/biaryl + amine-bearing cyclic ring at the 4-position (piperidine derivatives)
- The Markush allows numerous “tail” variations around the nitrogen-bearing ring and aryl substitutions, but the scaffold and substitution pattern stay recognizable.
Where scope is weakest (critical weakness)
The weakness is that claim 1’s Markush is broad, but the exemplified compounds appear to sit inside a single medicinal-chemistry “series”. Broad claim language combined with a narrow demonstrated enablement and/or a specific target biology can create vulnerability:
- Enablement and written description risk if the application does not provide guidance across the full Markush range (especially for less common R² classes like multi-carbonyl/heteroatom-containing groups).
- Best mode risk if one or two exemplars dominate experimental support.
- Obviousness risk is magnified when the Markush permits obvious substitution patterns already known for the same scaffold and target class.
How do the enumerated examples define the practical “center of gravity”?
Claims 3 and 4 list dozens of specific quinolines, with and without hydrochloride salts.
Representative freebase examples (claim 3)
The claim text enumerates compounds including:
- 2-phenyl-4-(4-N,N-diethylamino-piperidin-1-yl)quinoline (I-3)
- 7-chloro-2-phenyl-4-(4-N,N-diethylamino-piperidin-1-yl)quinoline (II-3)
- 2-phenyl-4-([1,4']-bipiperidin-1'-yl)quinoline (III-3)
- 2-phenyl-4-(4-N-tert-butylamino-piperidin-1-yl)quinoline (IV-1)
- 2-phenyl-4-[(4-morpholin-4-yl)piperidin-1-yl]quinoline (V-1)
- 7-chloro-2-phenyl-4-{1-[4-(N,N-diethylamino)-piperidin-1-yl]-eth-1-yl}quinoline (XVI-3)
- 2-phenyl-4-[4-(N,N-diethylaminomethyl)-piperidin-1-yl]quinoline (XXVI-3)
- 2-phenyl-4-{1-[4-(morpholino)-piperidinyl]-eth-1-yl}quinoline (XLV-1)
These exemplars strongly suggest the medicinal backbone is fixed and the main degrees of freedom are:
- 7-substitution (often chloro)
- 2-substitution (phenyl, substituted phenyl, naphthyl, biphenyl)
- amine identity (diethylamino, tert-butylamino, morpholino-containing substituents, aminomethyl linkers, ethyl linkers)
- linker chemistry (direct attachment vs methylene vs ethyl)
Representative salt examples (claim 4)
Claim 4 enumerates the same families as hydrochloride salts plus at least:
- 2-phenyl-4-{2-[4-(N,N-diethylamino-piperidin-1-yl]-propan-2-yl}quinoline trifluoroacetate salt (XXV-6)
Center-of-gravity inference
The enumerated claims create a “practical claim set” that is much narrower than the full Markush universe. In litigation or freedom-to-operate, this often becomes the focus because:
- Expert testimony will track what was actually made/tested.
- Anticipation/obviousness prior art will likely map onto the same scaffold with similar amine substituents.
- Any non-exemplified Markush branch becomes a vulnerability in written description/enablement.
What does the patent try to protect beyond molecules?
Composition claims are broad and platform-like
Claims 9-24 include:
- Pharmaceutical composition with therapeutically effective amount of claim 1 compound + adjuvant/carrier (claim 9)
- Combination with anti-neoplastic agent(s) (claim 10, claim 22)
- Nanoparticle formulation (claims 11-17, 20)
- average size: 80 to 600 nm (claim 17)
- polymeric biodegradable nanoparticle: PLGA-type or PLA/PGA with constraints
- polymer specifications:
- Poly(DL-lactic-co-glycolic acid) with MW 7 to 240 kDa (claim 13)
- PLA/PGA ratio 95:5 to 50:50 (claim 13)
- lisosomal biodegradable composition (claim 14)
- nanoparticles associated with PEG covalently or non-covalently (claim 16)
- named nanoparticle items: PLGA nanoparticles, PLGA-PEG nanoparticles (block type AB, BA, ABA or BAB), and targeted nanoparticles (claim 20)
- targeted nanoparticles containing a signaling motif (claim 21)
This is a classic strategy: protect the API and the delivery form and the combination regimen, without tying delivery form strictly to the target mechanism.
Method claims are extremely wide in disease scope
Claims 25-29:
- Treatment/prevention of “proliferative and/or neoplastic disease” (claim 25)
- Disease categories (claim 26) including:
- carcinoma, leukemia, malignant lymphoma, malignant melanoma, myeloproliferative diseases, sarcoma, CNS tumor, germ-line tumor, testicular cancer, thyroid cancer, astrocytoma, colon cancer, melanoma, mixed type neoplasia
- Carcinoma types listed in claim 27 (broad organ list)
- Leukemia subtypes in claim 28 (broad list)
- CSC/tumor-initiating cell growth/differentiation inhibition method (claim 29)
Combination clause expands infringement surface
Claim 22 expands to combination with one or more anti-neoplastic agents with simultaneous, separate, or sequential use. This can matter because even if a competitor avoids the nanoparticle formulation, they might still fall into combination-use infringement if the claims are enforced and the regimen is practiced.
Is the claim set likely novel over the known quinoline-amine landscape?
The provided text does not include:
- the patent’s priority date,
- the patent’s family members,
- the identity of the inventor-assignee,
- or the underlying target/biological mechanism.
Without these, a complete novelty and obviousness determination across the US prior art is not executable to a litigation-grade standard.
What can be done from the claim text alone is a structure-driven risk map:
Chemical motifs likely to face prior art
The quinoline + substituted aryl at 2-position + amine-containing piperidine at 4-position is a motif class that appears frequently in kinase- and receptor-targeted medicinal chemistry. The risk increases because:
- The substituent set includes common pharmacophore variations: diethylamino tertiary amines, tert-butylamino, morpholine-like motifs, aminomethyl and ethyl linkers.
- The claim is permissive in aryl substitution (halogens, alkyl, alkoxy, cyano, nitro).
How the Markush range intensifies obviousness risk
Even if a specific example is novel, the Markush can cover obvious variants:
- Replace phenyl with substituted phenyl/biaryl/naphthyl.
- Replace diethylamino with tert-butylamino or morpholino analogs.
- Swap direct attachment for methylene/ethyl linkers.
- Swap salt forms.
If prior art shows the same scaffold and same “amine ring at quinoline 4-position,” the breadth can fail even with differences in salt or one substituent.
What is the patent landscape position implied by the claim strategy?
The claim set combines three layers of IP:
- API composition (formula claims)
- Delivery platform (nanoparticles, PLGA/PEG, size range)
- Indication broadening (treatment and combination with a long anti-neoplastic roster)
That combination tends to produce:
- Wider enforcement pathways in composition/method form
- More opportunities for patent overlap with later combination or formulation patents
- Higher risk that the API sub-claims must stand up under strict chemical novelty and non-obviousness review, while the formulation and method claims may be attacked as overbroad or obvious in view of generic nanoparticle delivery systems
Critical view: likely claim construction pain points
Markush clarity vs litigation ambiguity
The definitions rely on nested “optionally substituted” lists and multiple substituent classes. Construction disputes typically center on:
- Whether certain substituent combinations are excluded implicitly by the Markush logic.
- Whether linker definitions (L¹/L² with “(-R³)” patterns) admit unintended structures.
- Whether “heteroaromatic 5 to 9 membered ring comprising 1, 2 or 3 heteroatoms independently selected from O, N, and S” is limiting enough to exclude common rings that share motif atoms.
Method claims: “therapeutically active amount” and broad disease categories
The method claims are written at a high abstraction level:
- many cancers are encompassed
- no specific target, biomarker, dosing regimen, or mechanism is tied to the method claims
- combination with “one or more anti-neoplastic agents” is unbounded except by generic class inclusion
In enforcement, this can be strong for capture but weak if courts require evidence that the compound works across the claimed disease range.
Actionable assessment for business decisioning
If you are underwriting investment risk
- Treat the compound claims (1-8) as the core value driver, and expect them to be the primary battleground for novelty and non-obviousness.
- Treat nanoparticle claims (11-21, 24) as potentially enforceable but vulnerable if generic PLGA-PEG nanoparticle systems existed with predictable sizes and formulations.
- Treat combination/method claims (10, 22, 25-29) as a broad infringement umbrella, but assess enforceability based on proof of practicing the claimed combination/regimen and on whether prior art supports therapeutic use.
If you are planning competitive R&D (design-around)
The claim breadth suggests straightforward design-around levers are:
- Stay away from the quinoline scaffold + 4-position piperidine/amine motif, or
- Break the relationship between the quinoline and the specific amine ring/linker pattern (direct vs methylene vs ethyl linkers), or
- Avoid the combination use with the specified nanoparticle platform if that layer is essential for enforcement strategy.
Key Takeaways
- US 10,179,770 claims a quinoline + substituted aryl + amine-bearing piperidine family, with expansive Markush coverage and explicit enumerated exemplars that define a narrower “center of gravity.”
- The patent’s main strength is its layered IP strategy: API formula claims plus broad nanoparticle formulation and combination/method claims across cancers and CSC framing.
- The main weaknesses for enforceability are typical for broad Markush patents: enablement/written description exposure outside exemplified branches and obviousness risk where prior art likely covers the same quinoline-amine substitution patterns.
- Downstream claims create a wide enforcement umbrella, but they also increase vulnerability to attacks on overbreadth, generic formulation obviousness, and proof burdens for broad disease coverage.
FAQs
-
Which parts of US 10,179,770 most likely determine validity in court?
The compound Markush claims (1-8) typically drive validity because chemical anticipation/obviousness is litigated at the structural level.
-
How much does the nanoparticle layer expand infringement risk?
Claims 11-21 expand risk materially by covering PLGA/PLA-PGA, PEG association, nanoparticle size 80-600 nm, and targeted/signaling motif nanoparticles.
-
Do the enumerated examples narrow the claim’s practical scope?
Yes. Even with broad Markush language, litigation and proof tend to track the specific exemplars listed in claims 3-4 and the linked sub-formulas in claims 5-8.
-
Is the method claim scope limited to a specific tumor type?
No. Claims 25-29 are drafted to cover broad proliferative/neoplastic diseases, with extensive organ and leukemia subtype lists and a CSC growth/differentiation inhibition framing.
-
What design-around strategy is most credible from the claim text?
The highest-leverage approach is to avoid the core quinoline scaffold combined with the specific 4-position amine/piperidine linker pattern, since the Markush otherwise allows many straightforward substituent variants.
References
No external sources were provided or cited in the prompt content; therefore no APA citations can be listed.
More… ↓
⤷ Start Trial
|
